在用于目的地治疗的左心室辅助器件中,患者的决策
1Nurse Practitioner, Palliative and Geriatric Medicine Inova Fairfax Hospital, US.
International journal of palliative nursing
|March 22, 2024
概括
用左心室辅助器 (LVAD) 治疗目的地治疗的患者经常觉得在医疗保健决策中没有选择. 了解患者的决策对于有效的沟通和护理至关重要.
科学领域:
- 心脏病学 心脏病学
- 医疗器械技术 医疗器械技术
- 患者护理 患者护理
背景情况:
- 心力衰竭是死亡的一个重要原因.
- 左心室辅助器件 (LVAD) 为无法进行移植的末期心力衰竭患者提供了目的地治疗选择.
- 了解患者对LVAD的体验对于改善护理至关重要.
研究的目的:
- 探索接受左心室辅助装置 (LVAD) 作为目的地治疗的患者在植入后如何做出医疗保健决策.
- 在高级心力衰竭管理的背景下,确定影响患者决策的因素.
主要方法:
- 使用了一项定性描述性研究.
- 与11名参与者进行了半结构化的深度访谈.
- 该研究的重点是使用LVAD治疗目的地的患者.
主要成果:
- 带有LVAD的参与者表示,在他们的医疗保健决策中"没有选择"的感觉.
- 患者的决策过程受到复杂的认知因素的影响.
- 患者报告的信息和临床医生的理解之间存在潜在的断开.
结论:
- 对于LVAD患者来说,医疗保健决策是一个多方面的过程.
- 临床医生必须认识到患者的观点和潜在的沟通差距.
- 加强患者参与是导航当前和未来的医疗保健选择所必需的.
相关概念视频
Cardiac Catheterization III: Left Heart Catheterization
Left heart catheterization is an invasive diagnostic procedure used to evaluate the function and structure of the left side of the heart. It is generally performed to diagnose and treat cardiovascular conditions such as valve abnormalities, coronary artery disease, and congenital heart defects.Diagnostic and therapeutic purposesLeft heart catheterization serves various diagnostic and therapeutic purposes, including:Assessing coronary artery bypass grafts.Evaluating coronary artery disease in...
Heart Failure V: Medical Management
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
Heart Failure VI: Adjunct Therapies
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
Cardiomyopathy II: Dilated Cardiomyopathy
Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
Cardiomyopathy III: Hypertrophic Cardiomyopathy
Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
Cardiomyopathy V: Interprofessional Care
Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...


